[go: up one dir, main page]

TW200606151A - Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions - Google Patents

Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

Info

Publication number
TW200606151A
TW200606151A TW094112655A TW94112655A TW200606151A TW 200606151 A TW200606151 A TW 200606151A TW 094112655 A TW094112655 A TW 094112655A TW 94112655 A TW94112655 A TW 94112655A TW 200606151 A TW200606151 A TW 200606151A
Authority
TW
Taiwan
Prior art keywords
preparing
pharmaceutical compositions
antagonists
salts
selected cgrp
Prior art date
Application number
TW094112655A
Other languages
Chinese (zh)
Inventor
Stephan Georg Mueller
Klaus Rudolf
Philipp Lustenberger
Dirk Stenkamp
Marco Santagostino
Fabio Paleari
Gerhard Schaenzle
Kristen Arndt
Henri Doods
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW200606151A publication Critical patent/TW200606151A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to the CGRP antagonists of general formula, (I) wherein A, X, Q, and R1 to R3 are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, mixtures, and salts thereof, and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
TW094112655A 2004-04-22 2005-04-21 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions TW200606151A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004019492A DE102004019492A1 (en) 2004-04-22 2004-04-22 Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
TW200606151A true TW200606151A (en) 2006-02-16

Family

ID=35140095

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094112655A TW200606151A (en) 2004-04-22 2005-04-21 Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

Country Status (9)

Country Link
EP (1) EP1740577A2 (en)
JP (1) JP2007533689A (en)
AR (1) AR049422A1 (en)
CA (1) CA2565219A1 (en)
DE (1) DE102004019492A1 (en)
PE (1) PE20060186A1 (en)
TW (1) TW200606151A (en)
UY (1) UY28859A1 (en)
WO (1) WO2005103037A2 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220862B2 (en) 2002-06-05 2007-05-22 Bristol-Myers Squibb Company Calcitonin gene related peptide receptor antagonists
US7842808B2 (en) 2002-06-05 2010-11-30 Bristol-Myers Squibb Company Anti-migraine spirocycles
US7595312B2 (en) 2002-10-25 2009-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
DE10250082A1 (en) 2002-10-25 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
TW200524601A (en) 2003-12-05 2005-08-01 Bristol Myers Squibb Co Heterocyclic anti-migraine agents
DE102004015723A1 (en) 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
TW200533398A (en) 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
US7384930B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7384931B2 (en) 2004-11-03 2008-06-10 Bristol-Myers Squibb Company Constrained compounds as CGRP-receptor antagonists
US7449586B2 (en) 2004-12-03 2008-11-11 Bristol-Myers Squibb Company Processes for the preparation of CGRP-receptor antagonists and intermediates thereof
DE102004063752A1 (en) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of selected CGRP antagonists to combat menopausal hot flashes
DE102004063753A1 (en) * 2004-12-29 2006-07-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of selected CGRP antagonists in combination with other migraine medicines for the treatment of migraine
EP1770091A1 (en) * 2005-09-29 2007-04-04 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP-antagonists, process for their preparation as well as their use as medicaments
DE102005038831A1 (en) * 2005-08-17 2007-02-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg New N-acylalkoxycarbonyl-piperidine derivatives, useful as CGRP antagonists, for treating e.g. headaches, cardiovascular disease, skin disorders, morphine tolerance, and inflammatory diseases such as osteoarthritis and allergic rhinitis
US7834007B2 (en) 2005-08-25 2010-11-16 Bristol-Myers Squibb Company CGRP antagonists
DE102005050892A1 (en) * 2005-10-21 2007-04-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
JP2009539800A (en) * 2006-06-08 2009-11-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Treatment of gastrointestinal disorders with CGRP antagonists
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
US8198311B2 (en) 2006-11-01 2012-06-12 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
EP2386558B1 (en) 2007-10-18 2014-10-01 Boehringer Ingelheim International GmbH CGRP antagonists
EP2065381A1 (en) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP antagonists
US8829006B2 (en) 2007-11-22 2014-09-09 Boehringer Ingelheim International Gmbh Compounds
KR20130043198A (en) * 2010-07-16 2013-04-29 피라말 엔터프라이지즈 리미티드 Imidazoquinoline derivatives substituted as kinase inhibitors
MX2016004250A (en) 2013-10-07 2016-07-12 Bayer Pharma AG Cyclic thienouracil-carboxamides and use thereof.
GB201519194D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP receptor antagonists
GB201519195D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
GB201519196D0 (en) 2015-10-30 2015-12-16 Heptares Therapeutics Ltd CGRP Receptor Antagonists
EP3423436B1 (en) 2016-03-03 2020-09-16 Boehringer Ingelheim International GmbH Pyridinylmethyl carbamimidoylcarbamate derivatives and their use as aoc3 inhibitors
US10336729B2 (en) 2016-03-03 2019-07-02 Boehringer Ingelheim International Gmbh 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE266673T1 (en) * 1996-09-10 2004-05-15 Boehringer Ingelheim Pharma MODIFIED AMINO ACIDS, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
JP2002525371A (en) * 1998-09-30 2002-08-13 メルク シャープ エンド ドーム リミテッド Benzimidazolinyl piperidine as CGRP ligand
DE19937304C2 (en) * 1999-08-10 2003-08-21 Boehringer Ingelheim Pharma Use of CGRP antagonists to combat menopausal hot flashes
DE10300973A1 (en) * 2003-01-14 2004-07-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg New carboxylic acids and their esters, medicaments containing these compounds and processes for their preparation
TW200533398A (en) * 2004-03-29 2005-10-16 Bristol Myers Squibb Co Novel therapeutic agents for the treatment of migraine
DE102004015723A1 (en) * 2004-03-29 2005-10-20 Boehringer Ingelheim Pharma Selected CGRP antagonists, process for their preparation and their use as pharmaceuticals

Also Published As

Publication number Publication date
WO2005103037A2 (en) 2005-11-03
UY28859A1 (en) 2005-11-30
AR049422A1 (en) 2006-08-02
EP1740577A2 (en) 2007-01-10
WO2005103037A3 (en) 2006-01-12
PE20060186A1 (en) 2006-04-18
DE102004019492A1 (en) 2005-11-10
CA2565219A1 (en) 2005-11-03
JP2007533689A (en) 2007-11-22

Similar Documents

Publication Publication Date Title
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
TW200602338A (en) Selected CGRP antagonists, process for preparing them and their use as pharmaceutical compositions
WO2009065919A3 (en) Organic compounds
WO2009065920A3 (en) Compounds
TW200603799A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
MXPA05004188A (en) Selected cgrp antagonists, method for production and use thereof as medicament.
MX2010003849A (en) Cgrp antagonists.
WO2009065922A3 (en) Organic compounds
NO20052496L (en) Selected CGRP antagonists, methods for their preparation and use thereof as drugs.
WO2007036532A3 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
TW200519106A (en) Organic compounds
ZA200604719B (en) DPP-IV inhibitors
MY146623A (en) Substituted prolinamides, manufacturing, and the use thereof as medicaments
YU30902A (en) Novel cyclopropanes as cgrp antagonists, medicaments containing said compounds and method for the production thereof
MX2010001020A (en) Organic compounds.
PL1620425T3 (en) Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
TW200738692A (en) New substituted glycinamides, process for their manufacture and use thereof as medicaments
WO2009034029A3 (en) 1-substituted 4-heterocyclylpiperidines for use as cgrp antagonists
NO20070089L (en) DPP-IV inhibitors
TW200800962A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
TW200740795A (en) Selected CGRP antagonists, processes for preparing them and their use as pharmaceutical compositions
TW200606153A (en) Process for producing pyridine derivatives of Nk-1 receptor antagonist
WO2009065921A3 (en) Novel compounds
NO20073758L (en) 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as CGRP antagonists